Safety of Cyclophosphamide Therapy in Autoimmune Rheumatic Diseases
Cyclophosphamide (CYC) is one of the most potent antineoplastic and immunosuppressant agents. It is used as a drug of choice in many organ-threatening manifestations of systemic autoimmune rheumatic diseases (AIRDs) such as lupus nephritis, antineutrophil cytoplasmic antibody-associated vasculitis,...
Saved in:
| Main Authors: | Ramaswamy Subramanian, Himanshu Pathak, Vinod Ravindran |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2019-01-01
|
| Series: | Indian Journal of Rheumatology |
| Subjects: | |
| Online Access: | http://www.indianjrheumatol.com/article.asp?issn=0973-3698;year=2019;volume=14;issue=2;spage=127;epage=135;aulast=Subramanian |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cyclophosphamide and mycophenolate mofetil as induction therapy in lupus nephritis
by: Božić-Majstorović Ljubinka, et al.
Published: (2024-01-01) -
End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India
by: V Jayaprakash, et al.
Published: (2020-01-01) -
Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: outcomes at a tertiary care centre in Lahore, Pakistan
by: Muhammad Ahmed Saeed, et al.
Published: (2024-04-01) -
Effect of tacrolimus with mycophenolate mofetil or cyclophosphamide on the renal response in systemic lupus erythematosus patients
by: Siqin Sun, et al.
Published: (2024-12-01) -
Mycophenolate mofetil versus cyclophosphamide, in combination with prednisolone for lupus nephritis induction treatment: Findings from a prospective observational study
by: Rakhesh LR, et al.
Published: (2025-07-01)